<VariationArchive VariationID="417619" VariationName="NM_001386393.1(PANK2):c.1096_1099del (p.Met366fs)" VariationType="Deletion" Accession="VCV000417619" Version="1" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-06-23" DateCreated="2018-02-13" MostRecentSubmission="2018-02-13">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="404597" VariationID="417619">
      <GeneList>
        <Gene Symbol="PANK2" FullName="pantothenate kinase 2" GeneID="80025" HGNC_ID="HGNC:15894" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>20p13</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="20" Accession="NC_000020.11" start="3888781" stop="3929887" display_start="3888781" display_stop="3929887" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="20" Accession="NC_000020.10" start="3869485" stop="3904501" display_start="3869485" display_stop="3904501" Strand="+" />
          </Location>
          <OMIM>606157</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_001386393.1(PANK2):c.1096_1099del (p.Met366fs)</Name>
      <CanonicalSPDI>NC_000020.11:3916939:ATGA:</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>20p13</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="20" Accession="NC_000020.11" start="3916940" stop="3916943" display_start="3916940" display_stop="3916943" variantLength="4" positionVCF="3916939" referenceAlleleVCF="GATGA" alternateAlleleVCF="G" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="20" Accession="NC_000020.10" start="3897587" stop="3897590" display_start="3897587" display_stop="3897590" variantLength="4" positionVCF="3897586" referenceAlleleVCF="GATGA" alternateAlleleVCF="G" />
      </Location>
      <ProteinChange>M185fs</ProteinChange>
      <ProteinChange>M40fs</ProteinChange>
      <ProteinChange>M476fs</ProteinChange>
      <ProteinChange>M366fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000020.10" sequenceAccession="NC_000020" sequenceVersion="10" change="g.3897587_3897590del" Assembly="GRCh37">
            <Expression>NC_000020.10:g.3897587_3897590del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000020.11" sequenceAccession="NC_000020" sequenceVersion="11" change="g.3916940_3916943del" Assembly="GRCh38">
            <Expression>NC_000020.11:g.3916940_3916943del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_008131.3" sequenceAccession="NG_008131" sequenceVersion="3" change="g.33102_33105del">
            <Expression>NG_008131.3:g.33102_33105del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001324191.2" sequenceAccession="NM_001324191" sequenceVersion="2" change="c.553_556del">
            <Expression>NM_001324191.2:c.553_556del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001311120.1" sequenceAccession="NP_001311120" sequenceVersion="1" change="p.Met185fs">
            <Expression>NP_001311120.1:p.Met185fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001324193.2" sequenceAccession="NM_001324193" sequenceVersion="2" change="c.118_121del">
            <Expression>NM_001324193.2:c.118_121del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001311122.1" sequenceAccession="NP_001311122" sequenceVersion="1" change="p.Met40fs">
            <Expression>NP_001311122.1:p.Met40fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001386393.1" sequenceAccession="NM_001386393" sequenceVersion="1" change="c.1096_1099del" MANESelect="true">
            <Expression>NM_001386393.1:c.1096_1099del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001373322.1" sequenceAccession="NP_001373322" sequenceVersion="1" change="p.Met366fs">
            <Expression>NP_001373322.1:p.Met366fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_024960.6" sequenceAccession="NM_024960" sequenceVersion="6" change="c.553_556del">
            <Expression>NM_024960.6:c.553_556del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_079236.3" sequenceAccession="NP_079236" sequenceVersion="3" change="p.Met185fs">
            <Expression>NP_079236.3:p.Met185fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_153638.4" sequenceAccession="NM_153638" sequenceVersion="4" change="c.1426_1429del">
            <Expression>NM_153638.4:c.1426_1429del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_705902.2" sequenceAccession="NP_705902" sequenceVersion="2" change="p.Met476fs">
            <Expression>NP_705902.2:p.Met476fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_153640.4" sequenceAccession="NM_153640" sequenceVersion="4" change="c.553_556del">
            <Expression>NM_153640.4:c.553_556del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_705904.1" sequenceAccession="NP_705904" sequenceVersion="1" change="p.Met185fs">
            <Expression>NP_705904.1:p.Met185fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="non-coding">
          <NucleotideExpression sequenceAccessionVersion="NR_136715.2" sequenceAccession="NR_136715" sequenceVersion="2" change="n.997_1000del">
            <Expression>NR_136715.2:n.997_1000del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001619" Type="non-coding transcript variant" DB="SO" />
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_1016" sequenceAccession="LRG_1016">
            <Expression>LRG_1016:g.33102_33105del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_1016t2" sequenceAccession="LRG_1016t2">
            <Expression>LRG_1016t2:c.1096_1099del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="LRG_1016p2" sequenceAccession="LRG_1016p2" change="p.Met366fs">
            <Expression>LRG_1016p2:p.Met366fs</Expression>
          </ProteinExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_1016t1" sequenceAccession="LRG_1016t1">
            <Expression>LRG_1016t1:c.1426_1429del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="LRG_1016p1" sequenceAccession="LRG_1016p1" change="p.Met476fs">
            <Expression>LRG_1016p1:p.Met476fs</Expression>
          </ProteinExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_153638.3" sequenceAccession="NM_153638" sequenceVersion="3" change="c.1426_1429delATGA">
            <Expression>NM_153638.3:c.1426_1429delATGA</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef ID="CA658684233" DB="ClinGen" />
        <XRef Type="rs" ID="1555789557" DB="dbSNP" />
      </XRefList>
      <FunctionalConsequence Value="protein truncation">
        <XRef ID="0015" DB="Variation Ontology" />
      </FunctionalConsequence>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_001386393.1(PANK2):c.1096_1099del (p.Met366fs) AND Pigmentary pallidal degeneration" Accession="RCV000578477" Version="2">
        <ClassifiedConditionList TraitSetID="1251">
          <ClassifiedCondition DB="MedGen" ID="C0018523">Pigmentary pallidal degeneration</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description DateLastEvaluated="2016-11-05" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2016-11-05" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2018-02-13" MostRecentSubmission="2018-02-13">
        <ReviewStatus>no assertion criteria provided</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">28821231</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="1251" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="3087" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Pantothenate kinase-associated neurodegeneration</ElementValue>
                <XRef ID="MONDO:0009319" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Neuroaxonal dystrophy, late infantile</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hallervorden-Spatz disease</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Neurodegeneration with brain iron accumulation 1</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">PKAN NEUROAXONAL DYSTROPHY, JUVENILE-ONSET</ElementValue>
                <XRef Type="MIM" ID="234200" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">HARP SYNDROME</ElementValue>
                <XRef Type="MIM" ID="234200" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Pigmentary pallidal degeneration</ElementValue>
                <XRef ID="Pigmentary+pallidal+degeneration/9108" DB="Genetic Alliance" />
                <XRef ID="2992000" DB="SNOMED CT" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">PKAN</ElementValue>
                <XRef Type="MIM" ID="234200" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Preferred">NBIA1</ElementValue>
                <XRef Type="MIM" ID="234200" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">HARP</ElementValue>
                <XRef Type="MIM" ID="234200" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="6564" />
                <XRef ID="6564" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Pantothenate kinase-associated neurodegeneration (PKAN) is a type of neurodegeneration with brain iron accumulation (NBIA). The phenotypic spectrum of PKAN includes classic PKAN and atypical PKAN. Classic PKAN is characterized by early-childhood onset of progressive dystonia, dysarthria, rigidity, and choreoathetosis. Pigmentary retinal degeneration is common. Atypical PKAN is characterized by later onset (age &gt;10 years), prominent speech defects, psychiatric disturbances, and more gradual progression of disease.</Attribute>
                <XRef ID="NBK1490" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301663</ID>
                <ID Source="BookShelf">NBK1490</ID>
              </Citation>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">23447832</ID>
                <ID Source="BookShelf">NBK121988</ID>
              </Citation>
              <XRef ID="157850" DB="Orphanet" />
              <XRef ID="C0018523" DB="MedGen" />
              <XRef ID="MONDO:0009319" DB="MONDO" />
              <XRef Type="MIM" ID="234200" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="1076992" SubmissionDate="2017-04-13" DateLastUpdated="2018-02-13" DateCreated="2018-02-13">
        <ClinVarSubmissionID localKey="SUB2512256" submittedAssembly="GRCh38" title="SUB2512256" />
        <ClinVarAccession Accession="SCV000537313" DateUpdated="2018-02-13" DateCreated="2018-02-13" Type="SCV" Version="1" SubmitterName="Dr. Faghihi's Medical Genetic Center" OrgID="505525" OrganizationCategory="laboratory" OrgAbbreviation="FMGC" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2016-11-05">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation Type="general">
            <ID Source="PubMed">28821231</ID>
          </Citation>
          <Comment>An 8 years old Iranian girl was admitted to Namazi Hospital (Shiraz, Iran) in 2015 with clinical diagnosis of dystonia who was apparently normal before the age of 4. She developed bone fracture, muscle rigidity, abnormal movement, lack of coordination, chorea, and dystonia with seizure attacks. She was intellectually normal but she had speech problem due to medications she was taking which were Sirdalud (Tizanidine), Gabax, trihexidine and NA Valporate. Multiplanar multisequential MRI images through the brain with usual protocol were taken which demonstrated normal signal intensity of both cerebral hemispheres with no sign of mass or hemorrhage or ischemic infarction. No hydrocephalus or shift of midline structure was found. Posterior fossa structures including cerebral hemispheres showed normal signal intensity without any mass or hemorrhage or ischemic infarction. 7the-8the nerve root complexes appeared normal and pituitary gland was also normal with no sign of gross mass. No extra-axial mass or hematoma or fluid collection was observed. It is worth noting that generalized cortical atrophy was considerable which was more than that of expected for the patientâ€™s age. Mucosal thickening was noted at both ethmoidal maxillary sinuses due to sinusitis. Mild inflammatory change at right mastoid air cells and the â€˜â€˜eye-of-the-tigerâ€™â€™ sign in MRI imaging was remarkable (figure 1). But, M.R.I of the cervical spine without contrast showed normal features. Paraclinical examinations were also requested which showed increased level of alkaline phosphatase (ALP) (191 U/L) and creatine phosphokinase (CPK) (456 U/L).</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Autosomal recessive inheritance</Attribute>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>not applicable</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>not applicable</AffectedStatus>
              <Gender>female</Gender>
            </Sample>
            <Method>
              <NamePlatform>Illumina HiSeq 2000</NamePlatform>
              <TypePlatform>Next-generation exome sequencing</TypePlatform>
              <Description>Whole Exome Sequencing was utilized for amplification and sequencing of all exons of protein-coding genes as well as some important other genomic regions. The DNA samples were sequenced, using Illumina HiSeq2000 machine and standard Illumina protocol for pair-end 99-nucleotide sequencing. Detail of sample alignment is listed below in Table 1. Briefly, next generation sequencing was performed to sequence close to 100 million reads on Illumina HiSeq2000 Sequencer. In general, test platform examined &gt;95% of the targeted regions with sensitivity of above 99%. In this test, point mutations and micro-insertion/deletions and duplication (&lt;20bp) can be simultaneously detected. Bioinformatics analysis of the sequencing results was performed using BWA aligner [35], GATK [36] and annovar [37] open access software as well as public databases and standard bioinformatics software. Sanger sequencing and segregation studies: Whole blood samples were collected in EDTA tubes from family members of the proband and then genomic DNA was extracted from the peripheral blood lymphocytes by QIAamp DNA Blood Mini Kit (Germany) according to the manufacturer's instructions. After that, the genomic DNA concentration was measured by NanoDrop (ND1000, USA) and stored at âˆ’20 Â°C until use. To conï¬rm the novel identified mutation, PCR was performed for the proband and her parents (PCR condition are given in table 2) and amplified DNA was then subjected to Sanger Sequencing using both forward and reverse primers according to ABI BigDye Terminator Cycle Sequencing Kit (Applied BiosystemsÂ®, USA). Sanger sequencing data was analyzed using NCBI BLAST and CodonCode Aligner software. Multiple sequence alignment analysis extracted from Polyphen website was also used to compare the amino acid sequence of human PANK2 protein with corresponding proteins across all Kingdoms. Following bioinformatics software and websites were also used to identify the features of PANK2 and the consequences of mutation in the given position of the protein: Polyphen, Mutation Taster, SIFT, and DISOPRED3 (Intrinsic disorder predictor).</Description>
              <MethodType>research</MethodType>
              <MethodAttribute>
                <Attribute Type="TestName">whole exome sequencing utilizing next generation sequencing on an Illumina platform</Attribute>
              </MethodAttribute>
            </Method>
            <ObservedData>
              <Attribute Type="Description">Whole Exome sequencing using Next Generation Illumina Sequencing was used to enrich all exons of protein-coding genes as well as some important other genomic regions in these two affected patients. A deleterious homozygous four-nucleotide deletion causing frameshift deletion in PANK2 gene (c.1426_1429delATGA, p.M476fs) was identified in an 8 years old girl with dystonia, bone fracture, muscle rigidity, abnormal movement, lack of coordination and chorea. The identified novel mutation were also confirmed by Sanger sequencing in the proband and their parents.</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="PANK2">
              <Name>pantothenate kinase 2</Name>
            </Gene>
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <GeneLocation>NM_153638.3:exon 5</GeneLocation>
          </Location>
          <FunctionalConsequence Value="protein truncation">
            <XRef DB="Variation Ontology" ID="0015" URL="http://purl.obolibrary.org/obo/VariO_0015" />
          </FunctionalConsequence>
          <AttributeSet>
            <Attribute Type="HGVS">NM_153638.3:c.1426_1429delATGA</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="234200" />
          </Trait>
        </TraitSet>
        <Citation Type="general">
          <ID Source="PubMed">28821231</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">28821231</ID>
        </Citation>
        <SubmissionNameList>
          <SubmissionName>SUB2512256</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="1076992" TraitType="Disease" MappingType="XRef" MappingValue="234200" MappingRef="OMIM">
        <MedGen CUI="C0018523" Name="Pigmentary pallidal degeneration" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

